PTPN22 and neoplasm: In addition to rapid exogenous blockade through direct PD-L1 binding, Zhou et al. [73] introduced a long-term endogenous therapeutic approach based on LyP1 peptide-modified OMVs (LOMVs) carrying PD-1 plasmids, which induced self-sustained PD-L1 blockade in tumor cells.